Evolent Q1 loss, beats on adjusted EPS, misses revenue, 2 new revenue agreements
Evolent Health posts Q1 loss, beats on adjusted EPS, misses revenue, unveils two new revenue agreements
- Evolent Health reported Q1 2026 loss of $0.24 per share on a GAAP basis.
- Adjusted Q1 2026 loss was $0.02 per share, beating analyst expectations for the quarter.
- Q1 2026 revenue totaled $496.2 million, below the $531.8 million analyst forecast.
- New Performance Suite expansion agreement is expected to generate over $200 million in annual revenue.
- Company reiterated full-year 2026 revenue and adjusted EBITDA guidance alongside its first quarter 2026 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.